Mayahara H, Murakami M, Kagawa K, et al. Acute morbidity of proton therapy for prostate cancer: the Hyogo Ion Beam Medical Center experience. Int J Radiat Oncol Biol Phys. 2007;69(2):434-43.
Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate [published correction appears in JAMA. 2008;299(8):898-899]. JAMA. 2005;294(10):1233-9.
Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(3):744-51.
Fontenot J et al. Risk of Secondary Malignant Neoplasms From Proton Therapy and Intensity-Modulated X-Ray Therapy for Early-Stage Prostate Cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):616-22.
Mendenhall N. Early Outcomes From Three Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):213-21.
Henderson R et al. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials. Acta Oncol. 2013 Apr;52(3):463-9.
Steneker M, Lomax A, Schneider U. Intensity modulated photon and proton therapy for the treatment of head and neck tumors. Radiother Oncol. 2006;80(2):263-7.
Vernimmen FJ, Harris JK, Wilson JA, Melvill R, Smit BJ, Slabbert JP. Stereotactic proton beam therapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2001;49(1):99-105.
Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys. 2005;63(2):362-72.
Zhang X et al. Intensity-Modulated Proton Therapy Reduces Normal Tissue Doses Compared With Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small Cell Lung Cancer: a Virtual Clinical Study. Int J Radiat Oncol Biol Phys. 2010;77(2):357-66.
Mizumoto M et al. Clinical Results of Proton-Beam Therapy for Locoregionally Advanced Esophageal Cancer. Strahlentherapie und Onkologie. 2010;186(9):482-8.
Miralbell R, Lomax A, Cella L, Scheider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys. 2002;54(3):824-9.
Wilson VC, McDonough J, Tochner Z. Proton beam irradiation in pediatric oncology: an overview. J Pediatr Hematol Oncol. 2005 Aug;27(8):444-8.
Jarosek S, Elliott S, Virnig BA. Proton beam radiotherapy in the U.S. Medicare population: growth in use between 2006 and 2009: Data Points # 10. 2012 May 7. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK97147/ on May 22, 2013.
Chung CS, Keating N, Yock T, Tarbell N. Comparative analysis of second malignancy risk in patients treated with proton therapy versus conventional photon therapy. Int J Radiat Oncol Biol Phys. 2008;72(1):S8.
Macready N. The promise of protons in cancer therapy. J Natl Cancer Inst. 2012;104(9):648-9.
Sheets N et al. Intensity-Modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control in Localized Prostate Cancer. JAMA. 2012;307(15):1611-20.
De Ruysscher D, Chang JY. Clinical Controversies: proton therapy for thoracic tumors. Semin Radiat Oncol. 2013;23(2):115-9.
Suit H et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol. 2008 Feb;86(2):148-53.